Potenza Therapeutics’ management team is highly experienced in the field of immuno-oncology and drug development. We have built a world-class cancer immunology R&D engine to create scientific breakthroughs in cancer immunology and discover life-saving therapeutics for the treatment of human cancers.

Dan J. Hicklin, Ph.D. - President and Chief Executive Officer

Dan Hicklin, Ph.D. is President and Chief Executive Officer at Potenza Therapeutics. He brings over 25 years of biopharmaceutical research and operations experience with particular expertise in oncology drug development. Dr. Hicklin co-founded Potenza in 2014. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also President of Trieza Therapeutics and a board member of Tizona Therapeutics, Harpoon Therapeutics, Maverick Therapeutics and the Scientific Advisory Board of Oncorus Therapeutics. Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston where he oversaw a number of immunotherapy projects including the development of Keytruda® (pembrolizumab). Dr. Hicklin began his career at ImClone Systems where he held several positions of increasing responsibility from 1987-2007, most recently as Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his M.S. and Ph.D. in microbiology & immunology from New York Medical College and earned his B.S. from the University of Iowa.

David Cordo - Chief Financial Officer

David Cordo is Chief Financial Officer at Potenza Therapeutics. Prior to serving as interim Chief Financial Officer for VC-backed life sciences companies including Potenza Therapeutics, Dicerna Pharmaceuticals, Epizyme, Mitobridge, Semma Therapeutics, and TransForm Pharmaceuticals, Mr. Cordo served as Treasurer of Millennium Pharmaceuticals and in senior finance management positions at Biogen Idec. He is a Certified Public Accountant and holds an MBA from Nichols College and a B.S./B.A. degree from Stonehill College.

Reid J. Leonard, Ph.D. - Chief Operating Officer

Reid Leonard is Chief Operating Officer at Potenza Therapeutics. He brings over 25 years of experience in basic and drug discovery research, external search and evaluation, business development, and venture capital investing. In addition to Potenza, Reid has participated in the formation of three other oncology startups funded by MPM Capital since 2014, including Tizona Therapeutics, TwentyEight-Seven Therapeutics, and Trieza Therapeutics. Dr. Leonard completed his academic training as a postdoctoral fellow in molecular pharmacology and physiology at the California Institute of Technology and holds a Ph.D. in neuroscience from Purdue University and a B.A. in biology and psychology from Brandeis University.

Eileen McC ullough - Vice President, Program and Portfolio Management

Eileen McCullogh is Vice President, Project and Program Management at Potenza Therapeutics. Prior to joining Potenza Therapeutics in 2015, Ms. McCullough was an external advisor to the strategic venture fund of Merck Research Laboratories. She also served as interim senior management for several healthcare startups. Before starting her career with startups, she worked for the biologics division of Medtronic. She has led the launch of over 15 products. She received her MBA from Harvard Business School and an A.B. in chemistry from Amherst College.

Cynthia Seidel-Dugan, Ph.D. - Chief Scientific Officer

Cynthia Seidel-Dugan, Ph.D. is Chief Scientific Officer at Potenza Therapeutics. Prior to joining Potenza Therapeutics in 2014, Dr. Seidel-Dugan served as Vice President, Biology of CoStim Pharmaceuticals. From 2005 to 2012 she served as Executive Director, Discovery Biology and New Targets, Oncology at Schering-Plough and Merck & Co. She also worked at Exelixis and ARIAD Pharmaceuticals. Teams she has led or worked with supported the discovery and clinical development of multiple small molecule and antibody therapeutics for oncology indications. Dr. Seidel-Dugan has co-authored over 17 peer-reviewed publications and is an inventor on 10 issued and pending patents. She completed her post-doctoral studies at the University of Pennsylvania in the laboratory of Dr. Joan Brugge and received a Ph.D. in micro/molecular biology from the University of Pennsylvania and a B.S. in biology from the College of William and Mary.

Gregory Sieczkiewicz, J.D., Ph.D. - Chief IP Counsel

Gregory Sieczkiewicz, J.D., Ph.D. is Chief IP Counsel at Potenza Therapeutics. Gregory Sieczkiewicz also serves as Managing Director and Chief IP Counsel at MPM Capital. Dr. Sieczkiewicz has provided in-house leadership as the architect of IP strategy in over a dozen venture-backed life sciences companies. He previously practiced IP prosecution and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Prior to entering the field of patent law, Dr. Sieczkiewicz completed his post-doctoral fellowship at the National Cancer Institute. He graduated from the College of the Holy Cross with an A.B. in Biology, received his PhD in cell, molecular and developmental biology from Tufts University School of Medicine and graduated magna cum laude from the evening program of Suffolk University Law School.